These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22735949)

  • 41. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A.
    Rönnmark J; Grönlund H; Uhlén M; Nygren PA
    Eur J Biochem; 2002 Jun; 269(11):2647-55. PubMed ID: 12047372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Replacing antibodies: engineering new binding proteins.
    Banta S; Dooley K; Shur O
    Annu Rev Biomed Eng; 2013; 15():93-113. PubMed ID: 23642248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and evaluation of radiolabeled tracers for tumor imaging.
    Wållberg H; Ståhl S
    Biotechnol Appl Biochem; 2013; 60(4):365-83. PubMed ID: 24033592
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineering bioactive peptide-based therapeutic molecules.
    Ryu JS; Cho AY; Seo SW; Min H
    Methods Mol Biol; 2014; 1088():35-50. PubMed ID: 24146395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering of Affibody Molecules.
    Ståhl S; Lindberg H; Hjelm LC; Löfblom J; Dahlsson Leitao C
    Cold Spring Harb Protoc; 2024 Nov; 2024(11):pdb.top107760. PubMed ID: 37491082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Affibody molecules as engineered protein drugs.
    Frejd FY; Kim KT
    Exp Mol Med; 2017 Mar; 49(3):e306. PubMed ID: 28336959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Alternative scaffold proteins].
    Petrovskaia LE; Shingarova LN; Dolgikh DA; Kirpichnikov MP
    Bioorg Khim; 2011; 37(5):581-91. PubMed ID: 22332353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances of affibody molecules in biomedical applications.
    Zhang L; Zhang H
    Bioorg Med Chem; 2024 Nov; 113():117923. PubMed ID: 39278106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bio-orthogonal and combinatorial approaches for the design of binding growth factors.
    Ito Y; Tada S
    Biomaterials; 2013 Oct; 34(31):7565-74. PubMed ID: 23859658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Affibody-Binding Ligands.
    Barozzi A; Lavoie RA; Day KN; Prodromou R; Menegatti S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.
    Kruziki MA; Bhatnagar S; Woldring DR; Duong VT; Hackel BJ
    Chem Biol; 2015 Jul; 22(7):946-56. PubMed ID: 26165154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Programmable Bio-surfaces for Biomedical Applications.
    Shiba K
    Adv Exp Med Biol; 2017; 1030():1-20. PubMed ID: 29081047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer.
    De A; Kuppusamy G; Karri VVSR
    Int J Biol Macromol; 2018 Feb; 107(Pt A):906-919. PubMed ID: 28935537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Construction and Validation of a New Naïve Sequestrin Library for Directed Evolution of Binders against Aggregation-Prone Peptides.
    Hjelm LC; Lindberg H; Ståhl S; Löfblom J
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614273
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bacterial Cell Display for Selection of Affibody Molecules.
    Dahlsson Leitao C; Ståhl S; Löfblom J
    Methods Mol Biol; 2023; 2681():99-112. PubMed ID: 37405645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engineering antibodies and proteins for molecular in vivo imaging.
    Romer T; Leonhardt H; Rothbauer U
    Curr Opin Biotechnol; 2011 Dec; 22(6):882-7. PubMed ID: 21708456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in the application of expressed protein ligation to protein engineering.
    Hofmann RM; Muir TW
    Curr Opin Biotechnol; 2002 Aug; 13(4):297-303. PubMed ID: 12323349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Scaffolds for engineering novel binding sites in proteins.
    Nygren PA; Uhlén M
    Curr Opin Struct Biol; 1997 Aug; 7(4):463-9. PubMed ID: 9266166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.